-
February 13, 2013
Amgen (AMGN) recently provided an update on its long-term strategy. The company said that it intends to focus on the ...
-
February 12, 2013
MannKind Corporation's (MNKD) loss of 23 cents per share in the fourth quarter of 2012 was wider than the Zacks ...
-
February 11, 2013
Biogen Idec (BIIB) and partner, Swedish Orphan Biovitrum recently presented encouraging data on their hemophilia ...
-
February 11, 2013
Genetic products company, Affymetrix Inc. (AFFX), inked a 'Powered by Affymetrix' ("PbA") Program agreement with ...
-
February 04, 2013
Elan Corporation plc (ELN) recently decided to sell its remaining 7.8 million ordinary shares in Alkermes plc (ALKS) ...
-
February 01, 2013
Alkermes plc (ALKS) reported earnings of 14 cents per share in the third quarter of fiscal 2013 (ended December 31, ...
-
February 01, 2013
Global genetic devices maker, Affymetrix Inc.'s (AFFX) fourth-quarter 2012 adjusted loss of 2 cents per share was in ...
-
January 25, 2013
Biogen Idec (BIIB) recently announced positive top-line data on its phase III multiple sclerosis candidate, ...
-
January 23, 2013
Arena Pharmaceuticals Inc. (ARNA) recently received 'The Day 180 List of Outstanding Issues' from the European ...
-
January 21, 2013
We are impressed by the expanded product portfolio at Alkermes (ALKS) following its purchase of Elan's EDT unit. The ...
-
January 09, 2013
Alkermes plc (ALKS) recently reaffirmed its view for fiscal 2013 (ending March 31, 2013). The company continues to ...
-
January 04, 2013
Alkermes plc (ALKS) recently announced positive results from a phase I study on its new antipsychotic candidate, ...
-
December 27, 2012
Elan Corporation, plc (ELN), a neuroscience-based biotechnology company, recently completed the separation of a ...
-
November 16, 2012
We are reverting to a Neutral recommendation on Alkermes plc (ALKS) from Outperform as we believe that the stock is ...
-
November 05, 2012
Alkermes plc (ALKS) reported earnings of 3 cents per share (including depreciation and stock-based compensation ...
-
October 26, 2012
We are upgrading Alkermes, Plc (ALKS) to Outperform following the impressive results delivered by the company in the ...
-
October 12, 2012
We recently upgraded Alkermes plc (ALKS) to Outperform from Neutral with a target price of $21.00. Our long term ...
-
October 01, 2012
Recently, Alkermes plc (ALKS) announced the successful completion of the refinancing of its previously outstanding ...
-
September 18, 2012
We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at ...
-
August 20, 2012
The market is having a bad day so far: the Nasdaq has slipped 0.2%; the S&P 500 is down 0.3%; and the Dow is trading ...
